PMID- 32249957
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211002
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 75
IP  - 10
DP  - 2020 Oct
TI  - Past, present, and future of anti-IgE biologics.
PG  - 2491-2502
LID - 10.1111/all.14308 [doi]
AB  - About 20 years after the identification of immunoglobulin E (IgE) and its key 
      role in allergic hypersensitivity reactions against normally harmless substances, 
      scientists have started inventing strategies to block its pathophysiological 
      activity in 1986. The initial concept of specific IgE targeting through the use 
      of anti-IgE antibodies has gained a lot of momentum and within a few years 
      independent research groups have reported successful generation of first murine 
      monoclonal anti-IgE antibodies. Subsequent generation of optimized chimeric and 
      humanized versions of these antibodies has paved the way for the development of 
      therapeutic anti-IgE biologicals as we know them today. With omalizumab, there is 
      currently still only one therapeutic anti-IgE antibody approved for the treatment 
      of allergic conditions. Since its application is limited to the treatment of 
      moderate-to-severe persistent asthma and chronic spontaneous urticaria, major 
      efforts have been undertaken to develop alternative anti-IgE biologicals that 
      could potentially be used in a broader spectrum of allergic diseases. Several new 
      drug candidates have been generated and are currently assessed in pre-clinical 
      studies or clinical trials. In this review, we highlight the molecular properties 
      of past and present anti-IgE biologicals and suggest concepts that might improve 
      treatment efficacy of future drug candidates.
CI  - (c) 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Guntern, Pascal
AU  - Guntern P
AUID- ORCID: 0000-0001-8840-8577
AD  - Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, 
      Switzerland.
AD  - Department of BioMedical Research, University of Bern, Bern, Switzerland.
AD  - Department of Rheumatology, Immunology and Allergology, University Hospital Bern, 
      Bern, Switzerland.
FAU - Eggel, Alexander
AU  - Eggel A
AUID- ORCID: 0000-0001-8746-3339
AD  - Department of BioMedical Research, University of Bern, Bern, Switzerland.
AD  - Department of Rheumatology, Immunology and Allergology, University Hospital Bern, 
      Bern, Switzerland.
LA  - eng
GR  - R01 HL141493/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200421
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Animals
MH  - *Anti-Allergic Agents
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Biological Products/therapeutic use
MH  - Humans
MH  - Mice
MH  - Omalizumab/therapeutic use
PMC - PMC7541678
MID - NIHMS1590258
OTO - NOTNLM
OT  - IgE
OT  - allergy treament
OT  - anti-IgE
OT  - b cells
OT  - basophils
OT  - biologics
OT  - mast cells
COIS- Conflicts of interest: The authors declare no conflict of interest.
EDAT- 2020/04/07 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/10/01
CRDT- 2020/04/07 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - 10.1111/all.14308 [doi]
PST - ppublish
SO  - Allergy. 2020 Oct;75(10):2491-2502. doi: 10.1111/all.14308. Epub 2020 Apr 21.